Role of bridging therapy during chimeric antigen receptor T cell therapy

Chimeric antigen receptor (CAR) T‐cell therapy has been approved for use in several relapsed/refractory hematologic malignancies and has significantly improved outcomes for these diseases. A number of different CAR T products are now being used in clinical practice and have demonstrated excellent ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhaskar, Shakthi T., Dholaria, Bhagirathbhai R., Sengsayadeth, Salyka M., Savani, Bipin N., Oluwole, Olalekan O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175845/
https://www.ncbi.nlm.nih.gov/pubmed/35844303
http://dx.doi.org/10.1002/jha2.335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175845/
https://www.ncbi.nlm.nih.gov/pubmed/35844303
http://dx.doi.org/10.1002/jha2.335

Ejemplares similares